POSTER #370 – Patient-Reported Outcomes in the Randomized, Phase III IMpower150 Study of Atezolizumab + Chemotherapy ± Bevacizumab vs Chemotherapy + Bevacizumab in 1L Nonsquamous Metastatic NSCLC

POSTER #370 – Patient-Reported Outcomes in the Randomized, Phase III IMpower150 Study of Atezolizumab + Chemotherapy ± Bevacizumab vs Chemotherapy + Bevacizumab in 1L Nonsquamous Metastatic NSCLC

Selected Poster From 2018 ASCO® Annual Meeting

Author(s): Martin Reck, Thomas Karagiannis, Thomas Wehler et al.
Copyright: © 2018 The Authors

 

 

By accessing this ePrint you agree to our terms and conditions
By accessing this content you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.
  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorised duplication or unauthorised distribution of the materials
  • You accept Springer Healthcare's Privacy Policy

 

Voucher code (required)
Your Name (required)
Your Email (required)